The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II

Initiation of pharmacological therapy in Parkinson's disease: when, why, and how

(2020) Rob M A de Bie et al.   LANCET NEUROLOGY

Correction to: Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study

(2020) Heinz Reichmann et al.   Translational Neurodegeneration

Randomized Delayed-Start Trial of Levodopa in Parkinson’s Disease

(2019) Constant V.M. Verschuur et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions

(2019) J. J. Ferreira et al.   EUROPEAN JOURNAL OF NEUROLOGY

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease

(2018) Susan H. Fox et al.   MOVEMENT DISORDERS

Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine

(2018) Margherita Fabbri et al.   MOVEMENT DISORDERS

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations

(2017) Andrew J. Lees et al.   JAMA Neurology

Opicapone: A Review in Parkinson’s Disease

(2016) Lesley J. Scott   DRUGS

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial

(2016) Joaquim J Ferreira et al.   LANCET NEUROLOGY

Levodopa therapy for Parkinson disease: Table

(2016) Peter A. LeWitt et al.   NEUROLOGY

The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa

(2014) R. Cilia et al.   BRAIN

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

(2014) PD MED Collaborative Group   LANCET

Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects

(2012) Luis Almeida et al.   CLINICAL PHARMACOKINETICS

When Do Levodopa Motor Fluctuations First Appear in Parkinson’s Disease

(2010) Fabrizio Stocchi et al.   EUROPEAN NEUROLOGY

Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase

(2010) László E. Kiss et al.   JOURNAL OF MEDICINAL CHEMISTRY

Levodopa in the treatment of Parkinson’s disease: an old drug still going strong

(2010) Angelo Antonini   Clinical Interventions in Aging

Levodopa-related wearing-off in Parkinson's disease: identification and management

(2009) Rajesh Pahwa et al.   CURRENT MEDICAL RESEARCH AND OPINION

Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD

(2008) R. Katzenschlager et al.   NEUROLOGY